Showing 4 posts of 4 posts found.


AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa

July 25, 2023
Research and Development AbbVie, Dermatology, HS, Rinvoq, clinical trial, upadacitinib

AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up trial assessing Rinvoq (upadacitinib) for …


AbbVie unveils new Phase 3 upadacitinib data in moderate to severe ulcerative colitis

December 10, 2020
Research and Development AbbVie, upadacitinib

AbbVie has announced data from the first of two Phase 3 studies investigating the efficacy of upadacitinib in treating moderate …


AbbVie’s Rinvoq smashes Phase 3 efficacy targets in atopic dermatits

July 22, 2020
Research and Development AbbVie, atopic dermatits, pharma, upadacitinib

AbbVie has lifted the curtain on data from the second Phase 3 trial investigating the efficacy of Rinvoq (upadacitinib) monotherapy …


AbbVie’s rheumatoid arthritis drug bests even its own blockbuster Humira at Phase 3

April 11, 2018
Research and Development AbbVie, Humira, pharma, rheumatoid arthritis, upadacitinib

AbbVie posted a strong showing this week from its JAK1 inhibitor upadacitinib, indicating that the drug outperformed even its own …

Latest content